Long-term follow-up after TRTP-101 treatment for scar
Official title: Long-Term Follow-up of Adults With Atrophic Scars Treated With TRTP-101 in Study CIC101-02
Run by CellinCells · NCT07892937 · Data updated 2026-11-12
This study checks in with people who previously received TRTP-101 to see if the treatment remains safe and helps with atrophic scar over several years.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 19 Years and up |
| Sex | All |
| Enrollment | 31 (estimated) |
| Sponsor | CellinCells Industry-sponsored |
| Locations | 1 site (Seoul) |
| Status | Recruiting |
| Started | September 11, 2026 |
| Main results expected | March 31, 2033 |
| Study ends | December 31, 2033 |
| Registry record updated | October 27, 2026 |
| Trial ID | NCT07892937 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Individuals who previously received TRTP-101 in CIC101-02 and provided informed consent for long-term follow-up.
✕Probably not a fit
Participants who do not experience ongoing improvement or who encounter safety concerns may not derive additional benefit from continued follow-up.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an observational long-term follow-up of participants who previously received TRTP-101 for atrophic scar. The study will monitor safety signals and any ongoing or new effects on the scar tissue over an extended period. Data collected may include adverse events and measures of scar appearance or function, with follow-up continuing for up to five years. Enrollment is limited to those who completed the prior CIC101-02 trial and who consent to continued participation. The trial is sponsored by CellinCells and conducted at Samsung Medical Center in Seoul, Korea.
Why it matters
Potential benefit: If TRTP-101 continues to show a favorable safety profile and beneficial effects, patients may experience sustained scar improvement with fewer long-term risks.
How similar studies have gone: Long-term follow-up studies of similar topical or tissue-modifying treatments have reported variable but informative safety data and signals of sustained benefit in some patients.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Received TRTP-101 in clinical trial CIC101-02 * Provided written informed consent to participate in this study Exclusion Criteria: * Judged to face significant health or safety risks by participating in this long-term follow-up study * Judged to be unable to continuously participate in or complete this long-term follow-up study
Where it's running
-
Samsung Medical Center
Seoul, South Korea Recruiting
Study contacts
- Principal investigator: JongHee Lee, MD — Department of Dermatology, Samsung Medical Center, Sungkyunkwan University School of Medicine
- Study coordinator: HyeJung Park, Director
- Email: hjpark@cellincells.com
- Phone: 82-70-4469-9115
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Exosome injections to improve atrophic facial scars
This trial will test whether injecting exosomes into atrophic facial scars improves their appearance and texture compared with saline injections in adults with multiple facial scars.
-
Safety and potential improvement of autologous fat-derived stem cells for adult facial atrophic scars
This study tests whether a single treatment with TRTP-101, made from the patient’s own fat-derived stem cells, is safe and may improve facial acne-related atrophic scars in adults.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.